Friday, September 23, 2016 9:00:25 AM
Idalopirdine shares the putative 5-HT6 antagonist MOA with Axovant’s RVT-101 but the analyst doesn't believe this result has predictive value for the ongoing '101 Phase III. Therefore he continues to see potential for this target in AD.
Key differences between the two candidates and Phase III programs:
-idalopirdine faced challenges on liver toxicity and potency
-this drug profile and protocol prioritized speed over thoroughness
In contrast, the analyst sees RVT-101 as the best-in-class 5-HT6 candidate and thinks its MINDSET trial is well designed to show clinical benefit. In addition, Axovant has already made significant progress on enrollment and in advance of 2017 results.
No change to the price target of $32.
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM